| Literature DB >> 30692997 |
Joseph F A Varga1, Maxwell P Bui-Marinos1, Barbara A Katzenback1.
Abstract
Amphibian skin is a mucosal surface in direct and continuous contact with a microbially diverse and laden aquatic and/or terrestrial environment. As such, frog skin is an important innate immune organ and first line of defence against pathogens in the environment. Critical to the innate immune functions of frog skin are the maintenance of physical, chemical, cellular, and microbiological barriers and the complex network of interactions that occur across all the barriers. Despite the global decline in amphibian populations, largely as a result of emerging infectious diseases, we understand little regarding the cellular and molecular mechanisms that underlie the innate immune function of amphibian skin and defence against pathogens. In this review, we discuss the structure, cell composition and cellular junctions that contribute to the skin physical barrier, the antimicrobial peptide arsenal that, in part, comprises the chemical barrier, the pattern recognition receptors involved in recognizing pathogens and initiating innate immune responses in the skin, and the contribution of commensal microbes on the skin to pathogen defence. We briefly discuss the influence of environmental abiotic factors (natural and anthropogenic) and pathogens on the immunocompetency of frog skin defences. Although some aspects of frog innate immunity, such as antimicrobial peptides are well-studied; other components and how they contribute to the skin innate immune barrier, are lacking. Elucidating the complex network of interactions occurring at the interface of the frog's external and internal environments will yield insight into the crucial role amphibian skin plays in host defence and the environmental factors leading to compromised barrier integrity, disease, and host mortality.Entities:
Keywords: amphibian; antimicrobial peptides (AMPs); anuran; epithelial cells; mucosal tissue; pattern recognition receptors (PRRs); skin immunology; skin microbiome
Mesh:
Substances:
Year: 2019 PMID: 30692997 PMCID: PMC6339944 DOI: 10.3389/fimmu.2018.03128
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1The physical, chemical, cellular, and microbiological innate immune barriers of frog skin. Frog skin, which is mucosal in nature, contains physical, chemical, cellular, and microbiological barriers that work together in defence against pathogen assault. Frog skin is composed of an epidermal and dermal layer, containing resident immune cells throughout the layers. The epidermis is comprised of stratified squamous epithelial cells in three distinct layers: the stratum corneum (1), stratum spinosum (2), and stratum germinativum. The dermis is largely comprised of connective tissue formed by collagenous fibres (black lines) in two layers, the spongious dermis (4) and the compact dermis (6), connected by collagenous columns (white star). In mainly terrestrial frogs, the Eberth-Kastschenko layer (5, thick blue line) separates the spongious dermal layer and compact dermal layer. Glands within the dermal layer include granular glands (a), mucosal glands (b), and small mixed glands (c) that secrete a slew of compounds, including mucus and antimicrobial peptides. Commensal bacteria overlay the frog skin layers, forming the microbiological barrier. The image was, in part, created with the aid of BioRender.
Minimal inhibitory concentration (MIC) of individual frog skin-derived antimicrobial peptides against amphibian bacterial pathogens.
| Dermaseptin-S1 | ALWKTMLKKLGTMALHAGKAALGAAADTISQGTQ | 0.5 | ( | ||
| Dermaseptin-S2 | ALWFTMLKKLGTMALHAGKAALGAAANTISQGTQ | 1 | ( | ||
| Dermaseptin-S3 | ALWKNMLKGIGKLAGKAALGAVKKLVGAES | 1 | ( | ||
| Dermaseptin-S4 | ALWMTLLKKVLKAAAKAALNAVLVGANA | 0.5 | ( | ||
| Dermaseptin-S5 | GLWSKIKTAGKSVAKAAAKAAVKAVTNAV | 35 | ( | ||
| Aurein 2.1 | GLLDIVKKVVGAFGSL | ND | ( | ||
| Dermaseptin-S1 | ALWKTMLKKLGTMALHAGKAALGAAADTISQGTQ | ND | ( | ||
| Ranalexin | FLGGLIKIVPAMICAVTKKC | ND | ( | ||
| CPF | GFASFLGKALKAALKIGANLLGGTPQQ-OH | ND | ( | ||
| Magainin I | GIGKFLHSAGKFGKAFVGEIMKS | ND | ( | ||
| Magainin II | GIGKFLHSAKKFGKAFVGEIMNS | ND | ( | ||
| Magainin II | GIGKFLHSAKKFGKAFVGEIMNS | ND | ( | ||
| PGLa | GMASKAGAIAGKIAKVALKAL.NH2 | ND | ( | ||
| Ascaphin-8 | GFKDLLKGAAKALVKTVLF.NH2 | 6 | ( | ||
| Aurein 2.1 | GLLDIVKKVVGAFGSL | 100 | ( | ||
| Leptoglycin | GLLGGLLGPLLGGGGGGGGGLL | 75 | ( | ||
| Magainin II | GIGKFLHSAKKFGKAFVGEIMNS | 30 μg/ml | ( | ||
| Magainin II | GIGKFLHSAKKFGKAFVGEIMNS | 50 | ( | ||
| Aurein 2.1 | GLLDIVKKVVGAFGSL | ND | ( | ||
| Magainin II | GIGKFLHSAKKFGKAFVGEIMNS | ND | ( | ||
| Aurein 2.1 | GLLDIVKKVVGAFGSL | 100 | ( | ||
| Magainin II | GIGKFLHSAKKFGKAFVGEIMNS | 50 | ( | ||
| Aurein 2.1 | GLLDIVKKVVGAFGSL | 100 | ( | ||
| Magainin II | GIGKFLHSAKKFGKAFVGEIMNS | 100 | ( | ||
| Aurein 2.1 | GLLDIVKKVVGAFGSL | 200 | ( | ||
| Magainin II | GIGKFLHSAKKFGKAFVGEIMNS | 50 | ( | ||
| Aurein 2.1 | GLLDIVKKVVGAFGSL | ND | ( | ||
| Magainin II | GIGKFLHSAKKFGKAFVGEIMNS | ND | ( | ||
| Aurein 2.1 | GLLDIVKKVVGAFGSL | 100 | ( | ||
| Magainin II | GIGKFLHSAKKFGKAFVGEIMNS | 100 | ( |
ND indicates not determined (i.e., at the level tested, the AMP was found to have no effect on the pathogen). MIC values are reported in μM unless indicated otherwise.
Minimal inhibitory concentration (MIC) of skin secretions containing frog skin-derived antimicrobial peptides against amphibian bacterial pathogens.
| Aurein 1.1, Aurein 3.1, Aurein 3.2, Aurein, 5.2, Aurein 3.3, Aurein 2.5, Aurein 1.2, Aurein 2.1, Aurein 2.6 | ND | ( | ||
| Uperin 7.1 | ND | ( | ||
| Aurein 3.1, Aurein 5.2, Aurein 3.2, Aurein 2.5, Aurein 2.1, Aurein 2.2, Aurein 2.3, Aurein 2.4 | ND | ( | ||
| Magainin I, Magainin II, PGQ, CPF 1-4, XPF, LPF, PGLa | ND | ( | ||
| Aurein 1.1, Aurein 3.1, Aurein 3.2, Aurein, 5.2, Aurein 3.3, Aurein 2.5, Aurein 1.2, Aurein 2.1, Aurein 2.6 | 62.5 μg/ml | ( | ||
| Uperin 7.1 | ND | ( | ||
| Aurein 3.1, Aurein 5.2, Aurein 3.2, Aurein 2.5, Aurein 2.1, Aurein 2.2, Aurein 2.3, Aurein 2.4 | 62.5 μg/ml | ( | ||
| Magainin I, Magainin II, PGQ, CPF 1-4, XPF, LPF, PGLa | 31.25 μg/ml | ( | ||
| Aurein 1.1, Aurein 3.1, Aurein 3.2, Aurein, 5.2, Aurein 3.3, Aurein 2.5, Aurein 1.2, Aurein 2.1, Aurein 2.6 | ND | ( | ||
| Uperin 7.1 | ND | ( | ||
| Aurein 3.1, Aurein 5.2, Aurein 3.2, Aurein 2.5, Aurein 2.1, Aurein 2.2, Aurein 2.3, Aurein 2.4 | ND | ( | ||
| Magainin I, Magainin II, PGQ, CPF 1-4, XPF, LPF, PGLa | 500 μg/ml | ( | ||
| Aurein 1.1, Aurein 3.1, Aurein 3.2, Aurein, 5.2, Aurein 3.3, Aurein 2.5, Aurein 1.2, Aurein 2.1, Aurein 2.6 | 250 μg/ml | ( | ||
| Uperin 7.1 | ND | ( | ||
| Aurein 3.1, Aurein 5.2, Aurein 3.2, Aurein 2.5, Aurein 2.1, Aurein 2.2, Aurein 2.3, Aurein 2.4 | 250 μg/ml | ( | ||
| Magainin I, Magainin II, PGQ, CPF 1-4, XPF, LPF, PGLa | 125 μg/ml | ( | ||
| Aurein 1.1, Aurein 3.1, Aurein 3.2, Aurein, 5.2, Aurein 3.3, Aurein 2.5, Aurein 1.2, Aurein 2.1, Aurein 2.6 | 500 μg/ml | ( | ||
| Uperin 7.1 | ND | ( | ||
| Aurein 3.1, Aurein 5.2, Aurein 3.2, Aurein 2.5, Aurein 2.1, Aurein 2.2, Aurein 2.3, Aurein 2.4 | 500 μg/ml | ( | ||
| Magainin I, Magainin II, PGQ, CPF 1-4, XPF, LPF, PGLa | 500 μg/ml | ( | ||
| Aurein 1.1, Aurein 3.1, Aurein 3.2, Aurein, 5.2, Aurein 3.3, Aurein 2.5, Aurein 1.2, Aurein 2.1, Aurein 2.6 | 125 μg/ml | ( | ||
| Uperin 7.1 | ND | ( | ||
| Aurein 3.1, Aurein 5.2, Aurein 3.2, Aurein 2.5, Aurein 2.1, Aurein 2.2, Aurein 2.3, Aurein 2.4 | 125 μg/ml | ( | ||
| Magainin I, Magainin II, PGQ, CPF 1-4, XPF, LPF, PGLa | 62.5 μg/ml | ( | ||
| Aurein 1.1, Aurein 3.1, Aurein 3.2, Aurein, 5.2, Aurein 3.3, Aurein 2.5, Aurein 1.2, Aurein 2.1, Aurein 2.6 | ND | ( | ||
| Uperin 7.1 | ND | ( | ||
| Aurein 3.1, Aurein 5.2, Aurein 3.2, Aurein 2.5, Aurein 2.1, Aurein 2.2, Aurein 2.3, Aurein 2.4 | ND | ( | ||
| Magainin I, Magainin II, PGQ, CPF 1-4, XPF, LPF, PGLa | ND | ( | ||
| Aurein 1.1, Aurein 3.1, Aurein 3.2, Aurein, 5.2, Aurein 3.3, Aurein 2.5, Aurein 1.2, Aurein 2.1, Aurein 2.6 | ND | ( | ||
| Uperin 7.1 | ND | ( | ||
| Aurein 3.1, Aurein 5.2, Aurein 3.2, Aurein 2.5, Aurein 2.1, Aurein 2.2, Aurein 2.3, Aurein 2.4 | ND | ( | ||
| Magainin I, Magainin II, PGQ, CPF 1-4, XPF, LPF, PGLa | ND | ( |
ND indicates not determined (i.e., at the level tested, the AMP was found to have no effect on the pathogen). MIC values are reported in μM unless indicated otherwise. For peptide mixtures, the antimicrobial peptides identified through mass spectrometry are summarized.
Inhibitory concentration 50 (IC50) of frog skin-derived antimicrobial peptides against amphibian viral pathogens.
| Dermaseptin-S1 | ALWKTMLKKLGTMALHAGKAALGAAADTISQGTQ | 12 | ( | ||
| Skin peptide mixture | ND | ( | |||
| Skin peptide mixture | ND | ( | |||
| Temporin A | FLPLIGRVLSGIL.NH2 | 58 | ( | ||
| Magainin II | GIGKFLHSAKKFGKAFVGEIMNS | ND | ( | ||
| PGLa | GMASKAGAIAGKIAKVALKAL.NH2 | ND | ( |
ND indicates not determined (i.e., at the level tested, the AMP or skin peptide mixture was found to have no effect on the pathogen). Values are reported in μM where available.
Minimal inhibitory concentration (MIC) of frog skin-derived antimicrobial peptides against amphibian fungal pathogens.
| Phylloseptin-L1 | LLGMIPLAISAISALSKL | 100 | ( | ||
| Dermaseptin-S1 | ALWKTMLKKLGTMALHAGKAALGAAADTISQGTQ | 23 | ( | ||
| Brevinin-1BYa | FLPILASLAAKFGPKLFCLVTKKC | 12.5 | ( | ||
| Brevinin-1BYc | FLPILASLAAKLGPKLFCLVTKKC | 6 | ( | ||
| Ranatuerin-2BYa | GILSTFKGLAKGVAKDLAGNLL DKFKCKITGC | 25 | ( | ||
| Ranatuerin-2BYb | GIMDSVKGLAKNLAGKLLDSLKCKITGC | 12.5 | ( | ||
| Metamorph AMP mixture | 12.5−50 μg/ml | ( | |||
| Ranalexin | FLGGLIKIVPAMICAVTKKC | 9 | ( | ||
| Ranatuerin-2Ma | GLLSSFKGVAKGVAKNLAGKLLEKLKCKITGC | 50 | ( | ||
| Ranatuerin-2Mb | GIMDSVKGVAKNLAAKLLEKLKCKITGC | 25 | ( | ||
| Temporin-1M | FLPIVGKLLSGLL.NH2 | 100 | ( | ||
| Adult AMP mixture | Temporin 1-M, Ranatuerin-2Mb, and Ranateurin-2Ma | >250 μg/ml | ( | ||
| Brevinin-1PRa | FLPVLTGLTPSIVPKLVCLLTKKC | 50 | ( | ||
| Brevinin-1PRb | FLPVLAGLTPSIVPKLVCLLTKKC | 12.5 | ( | ||
| Brevinin-1PRc | FFPMLAGVAARVVPKVICLITKKC | 6.25 | ( | ||
| Brevinin-1PRd | FLPMLAGLAASMVPKLVCLITKKC | 12.5 | ( | ||
| Esculentin-2PRa | GVFSFLKTGAKLLGSTLLKMAGKAGAEHLACKATNQC | 25 | ( | ||
| Esulentin-2PRb | GIFSALAAGVKLLGNTLFKMAGKAGAEHLACKATNQC | 12.5 | ( | ||
| Ranatuerin-2PRa | GILDSFKGVAKGVAKDLAGKLLDKLKCKITGC | 25 | ( | ||
| Rantuerin-2PRb | GILDTFKGVAKGVAKDLAVHMLENLKCKMTGC | 50 | ( | ||
| Rantuerin-2PRc | GILDSFKDVAKGVATHLLNMAKCKMTGC | 100 | ( | ||
| Rantuerin-2PRe | GIMNTVKDVATGVATHLLNMVKCKITGC | 100 | ( | ||
| Rantuerin-2PRf | GILDTFKGVAKGVAKDLAVHMLEKLKCKMTGC | 25 | ( | ||
| Rantuerin-2PRg | GILSSFKDVAKGVAKNVAAQLLDKLKCKITGC | 50 | ( | ||
| Rantuerin-2PRh | GILDTVKGVAKDVAAHLLNMVKCKITGC | 50 | ( | ||
| Temporin-PRb | FLPIITNLLGKLL.NH2 | 100 | ( | ||
| Temporin-PRc | NFLDTLINLAKKFI.NH2 | 25 | ( | ||
| Temporin-PRe | FLPLAMALGKLL.NH2 | >100 | ( | ||
| CPF | GFASFLGKALKAALKIGANLLGGTPQQ-OH | 12.5 | ( | ||
| CPF | GFASFLGKALKAALKIGANLLGGTPQQ-OH | 3.1 | ( | ||
| Magainin I | GIGKFLHSAGKFGKAFVGEIMKS | 50 | ( | ||
| Magainin II | GIGKFLHSAKKFGKAFVGEIMNS | 162 | ( | ||
| Magainin II | GIGKFLHSAKKFGKAFVGEIMNS | 100 | ( | ||
| PGLa | GMASKAGAIAGKIAKVALKAL.NH2 | 50 | ( | ||
| PGLa | GMASKAGAIAGKIAKVALKAL.NH2 | 3.1 | ( | ||
| Magainin II + PGLa (1:1 ratio) | 12.5 | ( | |||
| Magainin II | GIGKFLHSAKKFGKAFVGEIMNS | 12.5 | ( | ||
| PGLa | GMASKAGAIAGKIAKVALKAL.NH2 | 3.1 | ( | ||
| Magainin II + PGLa (1:1 ratio) | 0.8 | ( |
MIC values are reported in μM unless indicated otherwise. For peptide mixtures, the antimicrobial peptides identified through mass spectrometry are summarized.
Minimal inhibitory concentration (MIC) of frog skin-derived antimicrobial peptides against amphibian parasites.
| Adult AMP mixture | 65 | ( | ||
| Adult AMP mixture | 58 | ( | ||
| Adult AMP mixture | 35 | ( | ||
| Adult AMP mixture | 20 | ( | ||
| Adult AMP mixture | 19 | ( |
Toll-like receptor genes identified in frog species.
| TLR1 | ||||
| TLR2 | ||||
| TLR6 | ||||
| TLR10 | Not identified ( | |||
| TLR14 and TLR14-like | ||||
| TLR3 | ||||
| TLR4 | ||||
| TLR5 | ||||
| TLR7 | ||||
| TLR8 | ||||
| TLR9 | ||||
| TLR12 | ||||
| TLR13 | ||||
| TLR21 | ||||
| TLR22 |
X. tropicalis tlr genes shown in bold are predicted to contain introns, non-bolded genes are predicted to be intronless.
Soluble short form lacks the transmembrane and TIR domains.
Sequences were detected by RT-PCR with cDNA as a template, gene sequence structure not reported.